Changes in body composition in patients with left ventricular systolic dysfunction initiated on beta-blocker therapy.
BACKGROUND
Increasing body mass index, cholesterol and body fat are associated with a better prognosis in patients with left ventricular systolic dysfunction (LVSD). Beta-blocker usage is associated with changes in body composition and increased body fat. The present study investigated 12-month changes in body composition in patients with LVSD initiated on beta-blocker therapy.


METHODS
The relation between beta-blocker use and body composition was evaluated in 91 patients (75% male) with LVSD. Body composition was assessed by bioelectrical impedance.


RESULTS
Seventeen patients died during the study period. There was no statistical difference among beta-blocker usage, beta-blocker type, or changes in body fat, basal metabolic rate, impedance, fat-free mass, fat mass and total body water. There were no significant differences between any of these measures and beta-blocker usage.


CONCLUSIONS
After 12 months, changes in body composition were not found to be influenced by initiation of beta-blocker therapy in patients with LVSD.
Ingle
Lee
L
Carnegie Research Institute, Leeds Metropolitan University, Beckett's Park Campus, Leeds.
Rigby
Alan S
AS
Carroll
Sean
S
Butterly
Ron
R
King
Rod F
RF
Cooke
Carlton B
CB
Cleland
John Gjf
JG
Clark
Andrew L
AL